Lydia Tran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lydia Tran has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Ilir Maraj
Department of Internal Medicine, Cardiovascular Medicine, Yale School of Medicine, New Haven (J.P.H., I.M., R.T., R.C., V.K.W., C.J.H., A.D.E., J.G.A.).
3 shared publicationsRoy Taoutel
Department of Internal Medicine, Cardiovascular Medicine, Yale School of Medicine, New Haven (J.P.H., I.M., R.T., R.C., V.K.W., C.J.H., A.D.E., J.G.A.).
3 shared publicationsAlexander DelVecchio
Department of Internal Medicine Greenwich Hospital Greenwich Connecticut
2 shared publications- Cassius Iyad Ochoa Chaar
Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, Yale University School of Medicine, New Haven, CT
2 shared publications Christopher Howes
Department of Internal Medicine, Section of Cardiovascular Medicine Yale School of Medicine New Haven Connecticut
2 shared publicationsCindy Li
Department of Pharmacy Services Yale New Haven Hospital New Haven Connecticut
2 shared publications
Latest Publications
- 11 April 2026
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 84 (2) , 448-458.e3
Cost-effectiveness of antithrombotic therapies for peripheral arterial disease
- 11 April 2026
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 84 (2) , 448-458.e3
Cost-effectiveness of antithrombotic therapies for peripheral arterial disease
- Open Access
- 17 April 2021
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 4 (9) , 1134-1143
Pharmacists leadership in a medication shortage response: Illustrative examples from a health system response to the COVID‐19 crisis
As medication experts, clinical pharmacists play an active and dynamic role in a medication shortage response. Supplementing existing guidelines with an actionable framework of discrete activities to support effective medication shortage responses can expand the scope of pharmacy practice and improve patient care. Dissemination of best practices and illustrative, networked examples from health systems can support the adoption of innovative solutions. In this descriptive report, we document the translation of published shortage mitigation guidelines into system success through broad pharmacist engagement and the adaption and implementation of targeted strategies. The profound, wide‐reaching medication shortages that accompanied the coronavirus disease 2019 (COVID‐19) pandemic are used to highlight coordinated but distinct practices and how they have been combined to expand the influence of the pharmacy enterprise.
- 17 April 2021
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 4 (9) , 1134-1143
Open AccessPharmacists leadership in a medication shortage response: Illustrative examples from a health system response to the COVID‐19 crisis
As medication experts, clinical pharmacists play an active and dynamic role in a medication shortage response. Supplementing existing guidelines with an actionable framework of discrete activities to support effective medication shortage responses can expand the scope of pharmacy practice and improve patient care. Dissemination of best practices and illustrative, networked examples from health systems can support the adoption of innovative solutions. In this descriptive report, we document the translation of published shortage mitigation guidelines into system success through broad pharmacist engagement and the adaption and implementation of targeted strategies. The profound, wide‐reaching medication shortages that accompanied the coronavirus disease 2019 (COVID‐19) pandemic are used to highlight coordinated but distinct practices and how they have been combined to expand the influence of the pharmacy enterprise.
- 1 October 2020
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 13 (10) , 1220-1222
Temporal Trends in Arrhythmogenicity Related to Treatment of COVID-19 Infection
- 1 October 2020
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 13 (10) , 1220-1222
Temporal Trends in Arrhythmogenicity Related to Treatment of COVID-19 Infection
- Open Access
- 23 July 2020
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 77 (22) , 1874-1884
Dynamic pharmacy leadership during the COVID-19 crisis: Optimizing patient care through formulary and drug shortage management
Purpose: The coronavirus disease 2019 (COVID-19) pandemic has created unprecedented challenges for health systems around the world. We describe our approach to adapting the pharmacy leadership structure to address critical medication shortages through innovative data analysis, procurement strategies, and rapid implementation of medication policy. Summary: Yale New Haven Health deployed a system incident management command structure to effectively respond to the COVID-19 crisis. System pharmacy services adopted a similar framework to enable efficient communication and quick decision-making in key domains, including drug procurement and policy. By refining a model to project health-system medication needs, we were able to anticipate challenges and devise alternative treatment algorithms. By leveraging big data and creating a system knowledge base, we were able to consolidate reporting and coordinate efforts to ensure system success. Various procurement strategies were employed to ensure adequate supply, including frequent communication with our wholesaler, sourcing direct from suppliers, outsourcing of sterile products compounding to registered 503B outsourcing facilities, and acquisition of active pharmaceutical ingredients for compounding of essential medications. Strategic positioning of pharmacists within the health system’s incident command response teams and rapid adaption of drug use policy governance fueled accelerated response and nimble implementation. Communication was streamlined and executed via multiple outlets to reach a broad audience across the health system. Conclusion: With medication shortages posing a threat to patient care, dynamic pharmacy leadership proved essential to providing patient care at the height of the COVID-19 pandemic. System alignment and the rapid adaption of the existing framework for drug shortage management and medication use policy were crucial to success in crisis response.
- 23 July 2020
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 77 (22) , 1874-1884
Open AccessDynamic pharmacy leadership during the COVID-19 crisis: Optimizing patient care through formulary and drug shortage management
Purpose: The coronavirus disease 2019 (COVID-19) pandemic has created unprecedented challenges for health systems around the world. We describe our approach to adapting the pharmacy leadership structure to address critical medication shortages through innovative data analysis, procurement strategies, and rapid implementation of medication policy. Summary: Yale New Haven Health deployed a system incident management command structure to effectively respond to the COVID-19 crisis. System pharmacy services adopted a similar framework to enable efficient communication and quick decision-making in key domains, including drug procurement and policy. By refining a model to project health-system medication needs, we were able to anticipate challenges and devise alternative treatment algorithms. By leveraging big data and creating a system knowledge base, we were able to consolidate reporting and coordinate efforts to ensure system success. Various procurement strategies were employed to ensure adequate supply, including frequent communication with our wholesaler, sourcing direct from suppliers, outsourcing of sterile products compounding to registered 503B outsourcing facilities, and acquisition of active pharmaceutical ingredients for compounding of essential medications. Strategic positioning of pharmacists within the health system’s incident command response teams and rapid adaption of drug use policy governance fueled accelerated response and nimble implementation. Communication was streamlined and executed via multiple outlets to reach a broad audience across the health system. Conclusion: With medication shortages posing a threat to patient care, dynamic pharmacy leadership proved essential to providing patient care at the height of the COVID-19 pandemic. System alignment and the rapid adaption of the existing framework for drug shortage management and medication use policy were crucial to success in crisis response.
- 20 June 2020
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 31 (8) , 1904-1907
Incidence and determinants of QT interval prolongation in COVID‐19 patients treated with hydroxychloroquine and azithromycin
- 20 June 2020
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 31 (8) , 1904-1907
Incidence and determinants of QT interval prolongation in COVID‐19 patients treated with hydroxychloroquine and azithromycin
- Open Access
- 26 May 2020
- Published by Wiley
Incidence and Determinants of QT Interval Prolongation in COVID-19 Patients Treated with Hydroxychloroquine and Azithromycin
Combined use of hydroxychloroquine and azithromycin was globally adopted, in part due to paucity and high cost of alternative therapies. However the utility of these medications has been questioned; and thus safety becomes a major concern given clinical equipoise regarding efficacy. Both hydroxychloroquine and azithromycin continue to be administered in US clinical trials examining their potential role in prevention of infection, treatment of mild infection in ambulatory patients, and in combination with other medical regimens in treatment of patients with severe disease. These drugs also continue to be clinically utilized in hospitalized patients around the globe, often without continuous telemetry due to lack of resources. Concern regarding use of hydroxychloroquine without adequate rhythm monitoring in clinical trials has been recently expressed.1 A review of clinicaltrials.gov at the time of submission of this correspondence reveals actively recruiting trials of combined hydroxychloroquine/azithromycin with or without additional COVID-19 therapies, for both ambulatory and hospitalized patients within and outside the US. The potential for hydroxychloroquine and azithromycin to cause QT prolongation is counterbalanced by very low risk of pro-arrhythmia in the general population, and emerging evidence of relatively low risk of Torsades de Pointes (TdP) in COVID-19 patients.2,3,4,5 Thus delineation of the determinants of significant QTc prolongation and pro-arrhythmic risk for hydroxychloroquine/azithromycin is very important, especially given mounting evidence of inefficacy in COVID-19 treatment.
- 26 May 2020
- Published by Wiley
Open AccessIncidence and Determinants of QT Interval Prolongation in COVID-19 Patients Treated with Hydroxychloroquine and Azithromycin
Combined use of hydroxychloroquine and azithromycin was globally adopted, in part due to paucity and high cost of alternative therapies. However the utility of these medications has been questioned; and thus safety becomes a major concern given clinical equipoise regarding efficacy. Both hydroxychloroquine and azithromycin continue to be administered in US clinical trials examining their potential role in prevention of infection, treatment of mild infection in ambulatory patients, and in combination with other medical regimens in treatment of patients with severe disease. These drugs also continue to be clinically utilized in hospitalized patients around the globe, often without continuous telemetry due to lack of resources. Concern regarding use of hydroxychloroquine without adequate rhythm monitoring in clinical trials has been recently expressed.1 A review of clinicaltrials.gov at the time of submission of this correspondence reveals actively recruiting trials of combined hydroxychloroquine/azithromycin with or without additional COVID-19 therapies, for both ambulatory and hospitalized patients within and outside the US. The potential for hydroxychloroquine and azithromycin to cause QT prolongation is counterbalanced by very low risk of pro-arrhythmia in the general population, and emerging evidence of relatively low risk of Torsades de Pointes (TdP) in COVID-19 patients.2,3,4,5 Thus delineation of the determinants of significant QTc prolongation and pro-arrhythmic risk for hydroxychloroquine/azithromycin is very important, especially given mounting evidence of inefficacy in COVID-19 treatment.